Alpha-4 beta-1 ligands as targeting agents for cancer and autoimmune diseases
Highly potent ligands for activated alpha-4 beta-1 integrin have been identified by University of California, Davis researchers. These ligands can potentially be used as targeting agents for cancer as well as anti-inflammatory agents for autoimmune diseases.
Notable applications of these alpha-4 beta-1 ligands include:
The compounds for activated alpha-4 beta-1 integrin of the present invention have high affinity to human malignant lymphoid cells (both T- and B-cells, and including fresh malignant cells from patients with acute lymphocytic leukemia). Importantly, the binding affinities of these ligands are much higher than products currently developed.
|United States Of America||Issued Patent||8,486,370||07/16/2013||2007-154|
|United States Of America||Issued Patent||7,576,175||08/18/2009||2004-325|